These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25152941)

  • 21. What are the precautions with proton pump inhibitor use for reflux disease?
    Mospan CM
    JAAPA; 2015 Dec; 28(12):23-6. PubMed ID: 26595692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and medical management of Clostridium difficile infection.
    Shannon-Lowe J; Matheson NJ; Cooke FJ; Aliyu SH
    BMJ; 2010 Mar; 340():c1296. PubMed ID: 20228142
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
    Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
    Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overprescribing PPIs: Time for a hospital antacid policy on Clostridium difficile.
    Thachil J
    BMJ; 2008 Jan; 336(7636):109. PubMed ID: 18202039
    [No Abstract]   [Full Text] [Related]  

  • 25. [Interactions of proton pump inhibitors with oral bisphosphonates and fracture risk].
    Bartl R; von Tresckow E
    Dtsch Med Wochenschr; 2012 Apr; 137(15):804-5. PubMed ID: 22492419
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
    Abdallah J; Hassan T; Kyprianou A
    Am J Gastroenterol; 2014 Apr; 109(4):601-2. PubMed ID: 24698870
    [No Abstract]   [Full Text] [Related]  

  • 27. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
    Howell MD; Novack V; Grgurich P; Soulliard D; Novack L; Pencina M; Talmor D
    Arch Intern Med; 2010 May; 170(9):784-90. PubMed ID: 20458086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
    Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
    Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of long-term PPI therapy.
    Reimer C
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):443-54. PubMed ID: 23998981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly.
    Schuler A
    Geriatr Nurs; 2007; 28(4):225-9. PubMed ID: 17936957
    [No Abstract]   [Full Text] [Related]  

  • 31. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study.
    Leonard AD; Ho KM; Flexman J
    Intern Med J; 2012 May; 42(5):591-4. PubMed ID: 22616966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial: PPIs and recurrent C. difficile infection: no association?
    Leontiadis GI
    Am J Gastroenterol; 2013 Nov; 108(11):1802-3. PubMed ID: 24192949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clostridium difficile infection in hospitals: risk factors and responses.
    Louie TJ; Meddings J
    CMAJ; 2004 Jul; 171(1):45-6. PubMed ID: 15238495
    [No Abstract]   [Full Text] [Related]  

  • 34. Hospital-acquired Clostridium difficile infection among patients with type 2 diabetes mellitus in acute medical wards.
    Hassan SA; Rahman RA; Huda N; Wan Bebakar WM; Lee YY
    J R Coll Physicians Edinb; 2013; 43(2):103-7. PubMed ID: 23734349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clostridium difficile infection in intestinal transplant recipients.
    Goldenberg V; Berbel A; Camargo JF; Simkins J
    Transpl Int; 2018 Jan; 31(1):116-117. PubMed ID: 28926130
    [No Abstract]   [Full Text] [Related]  

  • 36. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.
    Hauben M; Horn S; Reich L; Younus M
    Int J Infect Dis; 2007 Sep; 11(5):417-22. PubMed ID: 17336566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients.
    Pappas M; Jolly S; Vijan S
    J Gen Intern Med; 2016 Apr; 31(4):364-71. PubMed ID: 26553337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Host and pathogen factors for Clostridium difficile infection and colonization.
    Loo VG; Bourgault AM; Poirier L; Lamothe F; Michaud S; Turgeon N; Toye B; Beaudoin A; Frost EH; Gilca R; Brassard P; Dendukuri N; Béliveau C; Oughton M; Brukner I; Dascal A
    N Engl J Med; 2011 Nov; 365(18):1693-703. PubMed ID: 22047560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric acid suppression and Clostridium difficile infection: is there a causal connection?
    Khanna S; Pardi DS
    Clin Gastroenterol Hepatol; 2012 May; 10(5):564; author reply 564. PubMed ID: 22289872
    [No Abstract]   [Full Text] [Related]  

  • 40. A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.
    Dubcenco E; Beers-Block PM; Kim LP; Schotland P; Levine JG; McCloskey CA; Bashaw ED
    Clin Transl Sci; 2017 Sep; 10(5):387-394. PubMed ID: 28618191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.